دورية أكاديمية
Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
| العنوان: | Stability of PCR targets for monitoring minimal residual disease in neuroblastoma. |
|---|---|
| المؤلفون: | Stutterheim J; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands., Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA |
| المصدر: | The Journal of molecular diagnostics : JMD [J Mol Diagn] 2012 Mar-Apr; Vol. 14 (2), pp. 168-75. Date of Electronic Publication: 2012 Jan 16. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893612 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1943-7811 (Electronic) Linking ISSN: 15251578 NLM ISO Abbreviation: J Mol Diagn Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2011- : New York : Elsevier Original Publication: Bethesda, MD : American Society for Investigative Pathology and the Association for Molecular Pathology, 1999- |
| مواضيع طبية MeSH: | Biomarkers, Tumor/*chemistry , Biomarkers, Tumor/*genetics , Bone Marrow/*pathology , Liver Neoplasms/*secondary , Neoplasm Recurrence, Local/*diagnosis , Neoplasm, Residual/*diagnosis , Neuroblastoma/*pathology, Bone Marrow/metabolism ; Humans ; Liver Neoplasms/genetics ; Liver Neoplasms/therapy ; Lymphatic Metastasis ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/therapy ; Neoplasm, Residual/genetics ; Neoplasm, Residual/therapy ; Neuroblastoma/genetics ; Neuroblastoma/therapy ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Remission Induction ; Tumor Cells, Cultured |
| مستخلص: | In neuroblastoma (NB) patients, minimal residual disease (MRD) can be detected by real-time quantitative PCR (qPCR) using NB-specific target genes, such as PHOX2B and TH. However, it is unknown whether the mRNA levels of these targets vary either during treatment or at relapse. If marker genes are not stably expressed, estimation of MRD levels in bone marrow (BM) or peripheral blood will be hampered. We studied the stability of a panel of qPCR markers in primary tumors at diagnosis compared with i) paired metastasis (n = 7), ii) treated (n = 10), and iii) relapse (n = 6) tumors. We also compared relative expression of the targets in iv) primary tumors and BM at diagnosis (n = 17), v) BM and peripheral blood at diagnosis (n = 20), vi) BM at diagnosis and during treatment (n = 26), and vii) BM from different puncture sides (n = 110). Especially at diagnosis, PCR target expression is quite stable. Accurate quantification is possible when expression level can be related to the primary tumor; however, PCR target expression can alter on treatment and at relapse. If the median value of relative expression of a panel of PCR targets is used, most variations due to treatment and outgrowth of subclones level out, allowing for reliable application and quantification of MRD-PCR targets in NB patients. (Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (RNA, Messenger) |
| تواريخ الأحداث: | Date Created: 20120119 Date Completed: 20120619 Latest Revision: 20151119 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.jmoldx.2011.12.002 |
| PMID: | 22251610 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1943-7811 |
|---|---|
| DOI: | 10.1016/j.jmoldx.2011.12.002 |